hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06346964, orgStudyIdInfo id: 2024-341, briefTitle: Self-Care Management in Older Adults, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-22, primaryCompletionDateStruct date: 2025-04-22, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Ankara Yildirim Beyazıt University, class: OTHER, descriptionModule briefSummary: Self-management of chronic diseases requires the ability to manage the symptoms, treatment, and lifestyle changes inherent in living with a chronic disease. Rational drug use by older adults is of particular importance. Mobile applications are being developed to facilitate the compliance of older adults with chronic diseases with medication treatment and to increase their disease self-management skills. The research was planned to strengthen participation in social life through rational drug use and disease self-care management in older adults with chronic diseases. The research will be conducted in a parallel group randomized controlled manner. In the research, a mobile application will be developed for the use of older adults. Older adults will be asked to use the mobile application for at least 6 months, and the scales will be re-administered face to face or online in the 3rd and 6th months of the intervention., conditionsModule conditions: Disease Self Management, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 72, type: ESTIMATED, armsInterventionsModule interventions name: mobile application, outcomesModule primaryOutcomes measure: Participation in social life (Social Inclusion Scale), primaryOutcomes measure: Participation in social life (Social Inclusion Scale), primaryOutcomes measure: Participation in social life (Social Inclusion Scale), eligibilityModule sex: ALL, minimumAge: 60 Years, maximumAge: 79 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ankara Yıldırım Beyazıt University, city: Ankara, state: Çubuk/Turkey, zip: 06760, country: Turkey, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06346951, orgStudyIdInfo id: LPan, briefTitle: Survey on the Current Status of IFD Diagnosis and Treatment by Intensive Care Physicians in Sichuan Province (IFS), acronym: IFS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2024-09-30, completionDateStruct date: 2024-09-30, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Sichuan Provincial People's Hospital, class: OTHER, descriptionModule briefSummary: The goal of this survey is to learn about the current status of the diagnosis and treatment of invasive fungal infections among intensive care physicians in Sichuan Province (IFS). Its primary focus lies on answering the following questions: ①awareness and proficiency in diagnosis and treatment; ②the use of antifungal medications; ③the application of microbiological identification and diagnostic methods. We aim to analyze the problems and deficiencies that existed among intensive care physicians in order to provide a basis for the development of targeted training and intervention measures., conditionsModule conditions: Invasive Fungal Infections, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, outcomesModule primaryOutcomes measure: The survey on the hospital's diagnostic and treatment standards and infrastructure for invasive fungal infections, primaryOutcomes measure: The survey on the awareness of an invasive fungal infection among intensive care physicians, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06346938, orgStudyIdInfo id: 2024WHXH001, briefTitle: The Clinical Significance of CT-based Biomarkers in the Classification and Prognosis of Bronchiectasis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-26, primaryCompletionDateStruct date: 2027-03-26, completionDateStruct date: 2027-03-26, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Wuhan Union Hospital, China, class: OTHER, descriptionModule briefSummary: As the third major chronic airway disease in China, bronchiectasis has a wide range of patients. However, the involved sites, morphological features and airway obstruction of bronchiectasis are varied, and clinical heterogeneity is high, making prognosis and severity difficult to evaluate. CT plays an important role in the diagnosis and classification of ramadasis. Based on this, we analyzed the CT findings of patients with bronchiectasis and followed up patients with bronchiectasis to understand their disease progression and prognosis, so as to further analyze the role of CT biomarkers in the type and prognosis of bronchiectasis diseases., conditionsModule conditions: Bronchiectasis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, outcomesModule primaryOutcomes measure: Frequency of acute exacerbations of bronchiectasis, secondaryOutcomes measure: Deterioration of lung function, secondaryOutcomes measure: Severity of dyspnoea, secondaryOutcomes measure: Degree of emphysema, secondaryOutcomes measure: Mucus plug score, secondaryOutcomes measure: Bhalla scores on CT of participants' lungs, secondaryOutcomes measure: Frequency of hospitalisation, secondaryOutcomes measure: Death, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Wuhan Union Hospital, city: Wuhan, state: Hubei, zip: 430022, country: China, contacts name: Xiaorong Wang, role: CONTACT, phone: 18627195231, phoneExt: +86, email: rong-100@163.com, geoPoint lat: 30.58333, lon: 114.26667, hasResults: False
protocolSection identificationModule nctId: NCT06346925, orgStudyIdInfo id: SHR8735-116, briefTitle: Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-07, completionDateStruct date: 2024-07, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Jiangsu HengRui Medicine Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: This study was designed as a single-center, randomized, open, two-cycle, cross-over trial. It is planned to enroll 18 healthy subjects, conditionsModule conditions: Adult Patients With Chronic Primary ITP, conditions: Adult Patients With SAA Who do Not Respond Well to Immunosuppressive Therapy, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 18, type: ESTIMATED, armsInterventionsModule interventions name: Herombopag Olamine Tablets, outcomesModule primaryOutcomes measure: Cmax, primaryOutcomes measure: AUC0-t, primaryOutcomes measure: AUC0-∞, secondaryOutcomes measure: Tmax, secondaryOutcomes measure: t1/2, secondaryOutcomes measure: CL/F, secondaryOutcomes measure: V/F, secondaryOutcomes measure: Incidence and severity of adverse events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: The Second Hospital of Anhui Medical Uniersity, city: Hefei, state: Anhui, zip: 230601, country: China, contacts name: Wei Hu, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 31.86389, lon: 117.28083, hasResults: False
protocolSection identificationModule nctId: NCT06346912, orgStudyIdInfo id: TXB2023022, briefTitle: CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2027-04-15, completionDateStruct date: 2027-04-15, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Zhejiang University, class: OTHER, collaborators name: Shanghai YaKe Biotechnology Ltd., descriptionModule briefSummary: Clinical Trial for the safety and efficacy of CD19-BAFF CAR-T cells therapy for refractory/relapsed B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma., conditionsModule conditions: Acute Lymphoblastic Leukemia,B-Cell, conditions: Non-hodgkin Lymphoma,B Cell, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: CD19-BAFF Targeted CAR T-cells, outcomesModule primaryOutcomes measure: Dose-limiting toxicity (DLT), primaryOutcomes measure: Incidence of treatment-emergent adverse events (TEAEs), secondaryOutcomes measure: Overall response rate ,ORR, secondaryOutcomes measure: Duration of remission ,DOR, secondaryOutcomes measure: Event-free survival, EFS, secondaryOutcomes measure: Overall survival, OS, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The first affiliated hospital of medical college of zhejiang university, city: Hangzhou, state: Zhejiang, zip: 310000, country: China, contacts name: He Huang, MD, role: CONTACT, phone: 86-13605714822, email: hehuangyu@126.com, contacts name: Yongxian Hu, MD, role: CONTACT, phone: +8615957162012, email: huyongxian2000@aliyun.com, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06346899, orgStudyIdInfo id: TAK-743-4012, briefTitle: A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08-14, primaryCompletionDateStruct date: 2025-08-13, completionDateStruct date: 2025-08-13, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Takeda, class: INDUSTRY, descriptionModule briefSummary: The Chinese health authority has approved lanadelumab to prevent Hereditary Angioedema (HAE) attacks in persons of 12 years and older. It has also approved icatibant to treat acute HAE attacks in persons 2 years and older.One of the main aims of this study is to learn about the number of HAE attacks in 1 month in Chinese persons with HAE during their treatment with lanadelumab. The other main aim is to learn how much time is needed to resolve acute HAE attacks when treated with icatibant. Other aims of this study are to learn more about side effects of lanadelumab and icatibant treatment as well as to collect additional information on the treatment with lanadelumab, such as the dose and how often it needs to be given, reasons for stopping the treatment with lanadelumab and how long it was taken until stopping. Participants will be treated by their doctors according to routine medical practice. Only data already available in the medical records of the participants will be reviewed and collected during this study., conditionsModule conditions: Hereditary Angioedema (HAE), designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 130, type: ESTIMATED, armsInterventionsModule interventions name: No intervention, outcomesModule primaryOutcomes measure: Monthly Rate of HAE Attacks for Each Lanadelumab-treated Participant During the Lanadelumab Exposure Period, primaryOutcomes measure: Median Time to Complete Attack Resolution for Icatibant Treated Participants, secondaryOutcomes measure: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) During Lanadelumab and Icatibant Exposure Period, secondaryOutcomes measure: Dosage of Lanadelumab Among Lanadelumab-treated Participant During the Lanadelumab Exposure Period, secondaryOutcomes measure: Frequency Administration of Lanadelumab Among Lanadelumab-treated Participant During the Lanadelumab Exposure Period, secondaryOutcomes measure: Number of Participants with Reasons of Discontinuation of Lanadelumab During the Lanadelumab Exposure Period, secondaryOutcomes measure: Time to Lanadelumab Discontinuation Among Lanadelumab-treated Participant During the Lanadelumab Exposure Period, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06346886, orgStudyIdInfo id: 23-011703, briefTitle: HTN App for HTN Control and Cardiovascular Health Among African-Americans, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-07, completionDateStruct date: 2025-07, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, collaborators name: Miami Heart Research Institute Inc., descriptionModule briefSummary: The purpose of this study is to test the hypertension (HTN) app-based intervention to see if it is more effective in improving uncontrolled HTN and HTN self-care among Africian-Americans from baseline to post-intervention (immediate, 3 months and 6 months post-intervention) as compared to the standard of care., conditionsModule conditions: Hypertension, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: FAITH! HTN app, outcomesModule primaryOutcomes measure: Absolute Change in Systolic Blood Pressure (BP), primaryOutcomes measure: HTN Self-Care as reported by H-SCALE(HTN Self-Care Activity Level Effects), secondaryOutcomes measure: Proportion of subjects reaching BP control, secondaryOutcomes measure: Change in BP as assessed by home BP cuff measurements, secondaryOutcomes measure: CV Health Knowledge as measured by module assessment scores, secondaryOutcomes measure: Hypertension (HTN) Knowledge as assessed by 11-item questionnaire, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic, city: Rochester, state: Minnesota, zip: 55905, country: United States, contacts name: Lainey Moen, role: CONTACT, phone: 507-266-7062, email: Moen.Lainey@mayo.edu, contacts name: Ashton Krogman, role: CONTACT, phone: (507) 266-2087, email: Krogman.Ashton@mayo.edu, contacts name: LaPrincess Brewer, M.D., M.P.H., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06346873, orgStudyIdInfo id: 23-008090, briefTitle: Demonstrating Efficacy of JOGO for the Treatment of Tremor, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09, primaryCompletionDateStruct date: 2026-09, completionDateStruct date: 2027-09, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: This research is being done to determine the effectiveness of a new treatment, called JOGO, for patients with functional tremor (FT). JOGO is a biofeedback device that has been shown to help patients with several conditions, e.g., chronic pain, migraine, and Parkinson's disease (PD)-related tremor. JOGO provides biofeedback by using wireless adhesive stickers, called surface electromyography, to get information about muscle activity. This information is then used to modify symptoms through a series of training sessions with a physical therapist and individual practice., conditionsModule conditions: Functional Neurological Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: JOGO, outcomesModule primaryOutcomes measure: Change in TETRAS scores 1 month, secondaryOutcomes measure: Change in TETRAS scores 2 months, secondaryOutcomes measure: Change in QUEST scores, secondaryOutcomes measure: Tremor prevalence, secondaryOutcomes measure: Tremor resolution 1 month, secondaryOutcomes measure: Tremor resolution 2 months, secondaryOutcomes measure: Change in BDI-II scores, secondaryOutcomes measure: Change in BAI scores, secondaryOutcomes measure: Change in Intolerance of Uncertainty Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic in Florida, city: Jacksonville, state: Florida, zip: 32224, country: United States, geoPoint lat: 30.33218, lon: -81.65565, hasResults: False
protocolSection identificationModule nctId: NCT06346860, orgStudyIdInfo id: 09.2024.241, briefTitle: Comparing Intrathecal Morphine With Modified Thoracoabdominal Nerve Block Through Perichondral Approach in Major Abdominal Surgery, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Marmara University, class: OTHER, descriptionModule briefSummary: Abdominal surgery causes severe postoperative pain due to retraction of the abdominal wall and direct manipulation of visceral organs. It leads to delayed postoperative recovery, increased postoperative morbidity and mortality. Intrathecal morphine, epidural analgesia and patient-controlled intravenous analgesia are used in postoperative pain management of abdominal surgeries. Intrathecal morphine is frequently used in many centers because it provides effective pain control. However; morphine has undesirable effects such as urinary retention, postoperative nausea and vomiting, and respiratory depression. Modified thoracoabdominal nerves block through perichondrial approach is a technique defined by the modification of the thoracoabdominal nerves block through perichondrial approach, in which local anesthetics are delivered only to the underside of the perichondral surface. The primary implication of this study is to compare postoperative pain scores and opioid consumption in patients undergoing major abdominal surgery with intrathecal morphine or modified thoracoabdominal nerves block through perichondrial approach., conditionsModule conditions: Opioid Use, conditions: Postoperative Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 56, type: ESTIMATED, armsInterventionsModule interventions name: Regional Block Comparison, outcomesModule primaryOutcomes measure: Comparison of postoperative opioid consumption between two groups via Patient Controlled Analgesia (PCA) device, secondaryOutcomes measure: Postoperative pain assessment with Numeric Rating Scale (NRS), secondaryOutcomes measure: Comparison of the frequency of treatment related complications, secondaryOutcomes measure: Participant satisfaction, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Marmara University School of Medicine, city: Istanbul, country: Turkey, contacts name: Beliz Bilgili, role: CONTACT, phone: 05362187927, email: belizbilgili@gmail.com, contacts name: Ayse Deniz Kayir, role: CONTACT, phone: 05465626316, email: kayir_95@hotmail.com, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06346834, orgStudyIdInfo id: PRO-sIPV-4002, briefTitle: Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains From Different Manufacturers, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2024-08-31, completionDateStruct date: 2024-12-30, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Sinovac Biotech Co., Ltd, class: INDUSTRY, descriptionModule briefSummary: To evaluate the immunogenicity and safety of sequential vaccination with Sinovac sIPV among infants who have received two doses of Biological Products Co., Ltd. sIPV., conditionsModule conditions: Poliomyelitis, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: sIPV, outcomesModule primaryOutcomes measure: Geometric Mean Increase (GMI), primaryOutcomes measure: Geometric Mean Titer (GMT), primaryOutcomes measure: Seropositivity rate, primaryOutcomes measure: Seroconversion rate, primaryOutcomes measure: Adverse reaction incidence, primaryOutcomes measure: Serious adverse events incidence, eligibilityModule sex: ALL, maximumAge: 12 Months, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06346821, orgStudyIdInfo id: WestChinaGBMTTFieldsV1.0, briefTitle: Tumor Treating Fields for Newly Diagnosed Glioblastoma: Two Emulated Trials With Chinese Multi-Hospital Based Real-World Data, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-07-04, primaryCompletionDateStruct date: 2024-04-01, completionDateStruct date: 2024-05-01, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Sichuan University, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to learn about the effectiveness of Optune® (Tumor Treating Fields) in newly diagnosed glioblastoma (GBM) in China. The main question it aims to answer are:* The efficacy of Optune® as an concomitant/adjuvant to radiation therapy (RT) and temozolomide (TMZ) alone in the treatment of newly diagnosed GBM patients.* The effectiveness of Optune® given concomitantly with RT and TMZ in newly diagnosed GBM patients, compared to RT and TMZ alone.Participants will:* Receive or not receive TTFields.* Concomitantly or adjuvantly receive TTFields., conditionsModule conditions: Glioblastoma Multiforme, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Optune® (Tumor Treating Fields), outcomesModule primaryOutcomes measure: Overall Survival (OS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: West China Hospital, status: RECRUITING, city: Chengdu, state: Sichuan, zip: 610041, country: China, contacts name: Lei Liu, PhD, MD, role: CONTACT, phone: +8618980606231, email: liuleihx@gmail.com, geoPoint lat: 30.66667, lon: 104.06667, hasResults: False